134eP Observed survival following treatment with leronlimab in patients with metastatic colorectal cancer - Annals of Oncology https://share.google/rB8Legiwvfa886AWs
"Four patients received leronlimab in combination with ongoing or new SOC regimens (n=2 FOLFOX, n=1 FOLFOX + bevacizumab and n=1 FOLFOXIRI + bevacizumab). One patient with a solitary hepatic metastasis underwent liver resection following a reduction (43%) after FOLFOX + leronlimab, and remains alive with no evidence of disease (NED) at ∼57 months. mOS from the first dose of leronlimab was 15.8 months (range 4.2-57), with n=3 achieving partial responses per RECIST 1.1.